Eras-4001

Overview

Eras-4001 is a potent, orally active pan- KRAS inhibitor with K d values of 110, 13 and 39 pM against wild-type, G12D and G12V mutant KRAS, respectively, and exhibits selectivity toward wild-type HRAS and NRAS. Eras-4001 inhibits ERK1/2 phosphorylation and cell viability in cancer cells. Eras-4001 induces tumor growth inhibition and regression in subcutaneous xenograft models. Eras-4001 can be used in research on non-small cell lung cancer , ovarian cancer , etc.

Application

Products | Products > Disease Areas > Lung Cancer | Products > Disease Areas > Respiratory Cancer | Products > Disease Areas > Ovarian Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Non-Small Cell Lung Cancer | Products > Disease Areas > Cancer | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Urogenital Disease | Products > Signaling Pathways > GPCR/G Protein | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Stem Cell/Wnt | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Immunotherapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > Ras | Products > Signaling Pathways > ERK

Product Information

• Catalog No.: HY-175870
• CAS No.: 3024878-19-8
• Molecular Formula: C36H39ClF4N8O3
• Molecular Weight: 743.19
• Purity: 98.27%
• Storage: Powder -20°C, 3 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Availability: In-stock

Source

Original product source